James Jones bought $807 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 168 shares at an average of $4.80, traded Jun 2, 2025, filed Jul 11, 2025.
Score components
- +15RoleDirector
- 0Trade size$807 at market
- -5Relative to holdingsUnder 1% of holdings (0.4%)
- +4Price context16% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.7%, 3m +15.0%, 6m +65.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-034816, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 2, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.20 | $42 | 43,176 | Jul 11, 2025 |
| Jun 3, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.61 | $45 | 43,184 | Jul 11, 2025 |
| Jun 4, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.75 | $46 | 43,192 | Jul 11, 2025 |
| Jun 5, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.46 | $44 | 43,200 | Jul 11, 2025 |
| Jun 6, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.57 | $45 | 43,208 | Jul 11, 2025 |
| Jun 9, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.94 | $48 | 43,216 | Jul 11, 2025 |
| Jun 10, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $6.00 | $48 | 43,224 | Jul 11, 2025 |
| Jun 11, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.57 | $45 | 43,232 | Jul 11, 2025 |
| Jun 12, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.67 | $45 | 43,240 | Jul 11, 2025 |
| Jun 13, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.81 | $46 | 43,248 | Jul 11, 2025 |
| Jun 16, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.32 | $43 | 43,256 | Jul 11, 2025 |
| Jun 17, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.61 | $45 | 43,264 | Jul 11, 2025 |
| Jun 18, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.52 | $44 | 43,272 | Jul 11, 2025 |
| Jun 20, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $5.29 | $42 | 43,280 | Jul 11, 2025 |
| Jun 23, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $4.61 | $37 | 43,288 | Jul 11, 2025 |
| Jun 24, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $3.91 | $31 | 43,296 | Jul 11, 2025 |
| Jun 25, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $3.27 | $26 | 43,304 | Jul 11, 2025 |
| Jun 26, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $2.71 | $22 | 43,312 | Jul 11, 2025 |
| Jun 27, 2025 | POpen-market purchase Common Stock10b5-1 | +8 | $2.60 | $21 | 43,320 | Jul 11, 2025 |
| Jun 30, 2025 | POpen-market purchase Common Stock10b5-1 | +16 | $2.74 | $44 | 43,336 | Jul 11, 2025 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,516 1,372 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $862 262 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $862 262 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $398 121 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $5,872 1,712 shares | +1% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $1,166 340 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $1,166 340 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $578 168 shares | +1% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,513 935 shares | +0% | |
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $807 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.